TERLIVAZ is currently the only approved pharmacologic treatment within the broader Acute Kidney Injury (AKI) landscape, having received FDA approval in September 2022 for hepatorenal syndrome-associated AKI (HRS-AKI), a high-mortality yet comparatively niche segment of AKI
The FDA approved it after two big studies with 469 adults without type 2 diabetes
Goat anti-mouse IgG or anti-rabbit IgG (Boster, Wuhan, China) conjugated to HRP was used as the secondary antibody
Whereas the present results show that 6/32 cases were GLP1R positive, representing 18% of all our PanIN cases, it should be stressed that the 6 positive cases were all of the PanIN 1/2 type, and that the 12 cases with PanIN 3 were all negative
- In the Triumph-4 Phase III trial involving adults with obesity and knee osteoarthritis, participants receiving the highest dose of retatrutide lost an average of 28.7% of their body weight over 68 weeks, and experienced a 75.8% decrease in pain scores associated with osteoarthritis-related knee pain
